Madhuri Tatiparthy
Overview
Explore the profile of Madhuri Tatiparthy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
4
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Amabebe E, Kumar A, Tatiparthy M, Kumar Kammala A, Taylor B, Menon R
Extracell Vesicles Circ Nucl Acids
. 2024 Dec;
5(2):297-328.
PMID: 39698538
Host-bacteria and bacteria-bacteria interactions can be facilitated by extracellular vesicles (EVs) secreted by both human and bacterial cells. Human and bacterial EVs (BEVs) propagate and transfer immunogenic cargos that may...
2.
Kumar Kammala A, Tatiparthy M, Thomas T, Bonam S, Boldogh I, Haitao H, et al.
Am J Reprod Immunol
. 2024 May;
91(5):e13861.
PMID: 38716765
Background: Maternal-fetal immunology is intricate, and the effects of mRNA-S maternal vaccination on immune regulation at the maternal-fetal interface require further investigation. Our study endeavors to elucidate these immunological changes,...
3.
Kao Y, Chen J, Kumari R, Ng A, Zintiridou A, Tatiparthy M, et al.
Cell Stem Cell
. 2024 Feb;
31(3):378-397.e12.
PMID: 38402617
Mechanisms governing the maintenance of blood-producing hematopoietic stem and multipotent progenitor cells (HSPCs) are incompletely understood, particularly those regulating fate, ensuring long-term maintenance, and preventing aging-associated stem cell dysfunction. We...
4.
Okoye-Okafor U, Javarappa K, Tsallos D, Saad J, Yang D, Zhang C, et al.
J Exp Med
. 2022 Sep;
219(11).
PMID: 36053753
Thrombocytopenia, prevalent in the majority of patients with myeloid malignancies, such as myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), is an independent adverse prognostic factor. Azacitidine (AZA), a mainstay...